Platinum
- Generic Name
- Platinum
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Eli Lilly’s Ebglyss for eczema, Novartis’ Kisqali for early breast cancer, Merck’s Keytruda for malignant pleural mesothelioma, J&J’s Rybrevant for advanced lung cancer, and AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis.
Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer
The European Commission approved zolbetuximab (Vyloy) plus chemotherapy for HER2-negative, Claudin 18.2-positive gastric and gastroesophageal junction cancers. Zolbetuximab, targeting CLDN18.2, showed improved progression-free and overall survival in phase 3 trials SPOTLIGHT and GLOW. Common side effects included vomiting, nausea, and decreased appetite.
Related Clinical Trials:
Merck/Daiichi Sankyo's ADC candidate shows promise in phase 3 lung cancer trial
Merck & Co and Daiichi Sankyo's late-stage trial of patritumab deruxtecan in EGFR-mutated NSCLC met primary endpoint of PFS, showing significant improvement over standard chemotherapy. The trial continues to assess overall survival, with plans to discuss findings with regulatory authorities.
Merck's Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment
Merck & Co. received FDA approval for Keytruda in malignant pleural mesothelioma, used with pemetrexed and platinum chemotherapy. The phase 2/3 trial showed a 21% reduction in death risk compared to chemotherapy alone, with median overall survival of 17.3 months.
FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma
FDA approves Keytruda plus pemetrexed and platinum chemotherapy as first-line treatment for inoperable pleural mesothelioma, following Keynote-483 trial results showing survival benefits and similar safety profile to chemotherapy alone.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
FDA approves Merck's Keytruda for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma, based on KEYNOTE-483 study showing improved overall survival and progression-free survival.
Patritumab Deruxtecan Demonstrates Significant Survival Improvement in Locally Advanced
Patritumab deruxtecan showed significant PFS improvement in EGFR-mutated NSCLC patients post-TKI treatment, outperforming standard platinum-based doublet chemotherapy in the HERTHENA-Lung02 trial. Daiichi Sankyo and Merck plan to discuss these findings with regulatory authorities.
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
FDA approves Merck's Keytruda plus pemetrexed and platinum chemotherapy as first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM), based on improved overall survival, progression-free survival, and overall response rate in the IND.227/KEYNOTE-483 trial.
Related Clinical Trials:
FDA Approves Pembrolizumab Plus Pemetrexed and Platinum Chemotherapy for Malignant
FDA approves pembrolizumab plus pemetrexed and platinum chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma, based on improved overall and progression-free survival in the KEYNOTE-483 trial.
Related Clinical Trials:
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
Merck & Co. wins first U.S. approval for Keytruda in malignant pleural mesothelioma, based on Phase 3 study showing improved survival with Keytruda plus chemotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath